ClinicalTrials.gg
Not yet recruitingNCT07103473Updated Aug 5, 2025

Interactive Binocular Treatment (I- BiT) in Adult Patients With Anisometropic Amblyopia

An interventional study of Interactive Binocular Treatment in Amblyopia, sponsored by Shahid Beheshti University of Medical Sciences. Not yet recruiting at 1 site in Iran. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Shahid Beheshti University of Medical Sciences · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as not yet recruiting.
Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Randomized
Ages
18 Years to 40 Years
Sex
All
01

Study summary

Amblyopia is one of the common, preventable and treatable causes of decreased acuity of one or both eyes without a specific organic cause. Common treatments include optical correction, patching (closing the healthy eye), perceptual learning, and drug treatments. The patient's low cooperation, reduction in effectiveness and long treatment period of common methods have led to the design of new treatments that eliminate these disadvantages, among which binocular vision treatments can be mentioned. The purpose of this study is to apply a new and innovative method under binocular conditions in the treatment of anisometropic amblyopia in adults. In this randomized clinical trial study, 30 people (15 patients in the case group and 15 patients in the control group) aged 18 to 40 years with amblyopia (decrease in best corrected vision worse than 0.3 logarithmic units in one of the eyes or the difference of the corrected minimum visual acuity of two lines between two eyes) in the form of two groups of 15 people (case and control) will be included in the study. Patients will be randomly divided into two groups: case and control. Interactive Binocular Treatment (I-BiT) is used in the case group and usual games without I-BiT system are used as placebo in the other group. For this purpose, the games will be presented in the control group in such a way that the two eyes will not be dissociated and the patient will see all the targets in the same way with his two eyes. I-BiT is a new method for the treatment of amblyopia in which a person plays age-appropriate games using special glasses in a 3D space. The stimuli are shown differently to the two eyes and both eyes are involved in the treatment process. The selection of people in two groups will be such that background variables such as age, sex, as well as the severity of amblyopia or vision loss in the two groups are the same and confounding factors are under control. First, all eye examinations such as measuring visual acuity, lateral vision, checking refractive errors with and without cycloplegic drops, checking the alignment of visual axes, and also checking the anterior and posterior segments of the eye are performed. After the definitive diagnosis of amblyopia, people in both groups will be asked to use the given virtual games in the same way for one month, 5 sessions per week, each session for 30 minutes. In order to control the amount of use of computer games by patients, the duration of time that people use games will be controlled and recorded online using software by design engineers. Patients will be examined before treatment, one month after treatment and also one month after stopping treatment.

02

Conditions studied

  • Amblyopia

Browse trials for

03

In context

Amblyopia

189 studies on the registry are indexed under Amblyopia; 41 are open to participants now.

This study's planned enrollment of 15 is below the median of 60 across 137 interventional studies indexed under Amblyopia.

Browse Amblyopia studies →

Lead sponsor

Shahid Beheshti University of Medical Sciences is the lead sponsor of 229 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  1. Age range from 18 to 40 years
  2. Best corrected visual acuity of 0.3 log units or worse in one eye
  3. Cases of mild and moderate anisometropic amblyopia (BCVA≤0.3)
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
15 participants (estimated)

Study arms

  • Active comparator
    Interactive Binocular Treatment

    Patients in this arm will receive the Interactive Binocular Treatment therapy as an intervention

    Device: Interactive Binocular Treatment

  • Placebo comparator
    Placebo

    Patients in this arm will receive no active treatment

    Device: Interactive Binocular Treatment

Interventions

  • DeviceInteractive Binocular Treatment

    Patients in the intervention group will be asked to play the games which will be designed based on the Interactive Binocular Treatment System and the patients in the placebo group will be asked to play games without the Interactive Binocular Treatment System.

06

What researchers measure

Primary outcomes

  1. Best corrected visual acuity

    The changes of the best corrected visual acuity after one month therapy will be measured as the primary outcome measure.

    Time frame: one month

Secondary outcomes

  1. Stereopsis

    The changes of stereopsis will be assessed after one month therapy.

    Time frame: one month

07

Study locations

1 site
  • Hamideh Sabbaghi
    Tehran, Tehran Province 16666, Iran
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07103473
Responsible party
Hamideh Sabbaghi (Assistant Professor, Shahid Beheshti University of Medical Sciences) — Principal investigator
First posted
Aug 5, 2025
Start date
Dec 10, 2025 (estimated)
Primary completion
Dec 10, 2025 (estimated)
Completion
Dec 29, 2025 (estimated)
Last update
Aug 5, 2025

Study contacts

Hamideh Faculty member, Assistant Professor
Contact
sabbaghi.opt@gmail.com
989120285930

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion